# 血漿分画製剤市場

> 血漿由来製品市場調査報告書 タイプ別 [第VIII因子濃縮物、第IX因子濃縮物、アルブミン、免疫グロブリン、抗トロンビンIII濃縮物、新鮮凍結血漿（FFP）]、用途（HIV、血友病A、血友病B、B型肝炎、C型肝炎、出血性疾患、低ガンマグロブリン血症、免疫不全疾患、その他）、最終ユーザー（病院＆クリニック、輸血センター、診断センター、その他）、地域（アメリカ、ヨーロッパ、アジア太平洋、中東＆アフリカ）—2035年までの予測

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.47%
- **2024:** $ 43.3 Billion
- **2025:** $ 46.6 Billion
- **2035:** $ 86.67 Billion
- **Key Players:** Grifols (ES), CSL Behring (AU), Takeda Pharmaceutical Company Limited (JP), Octapharma (CH), Kedrion S.p.A. (IT), Bio Products Laboratory (GB), LFB Group (FR), Hualan Biological Engineering Inc. (CN)

**Report ID:** MRFR/Pharma/0817-HCR · **Pages:** 80 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** September 22, 2026

**URL:** https://www.marketresearchfuture.com/reports/blood-plasma-derivatives-market-1325

---

## Market Summary

As per MRFR analysis, the Blood Plasma Derivatives Market Size was estimated at 43.3 USD Billion in 2024. The Blood Plasma Derivatives industry is projected to grow from 46.6 USD Billion in 2025 to 86.67 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 6.47% during the forecast period 2025 - 2035.

## Market Drivers

### Rising Demand for Immunoglobulins

The Global Blood Plasma Derivatives Market Industry experiences a notable surge in demand for immunoglobulins, primarily driven by their therapeutic applications in treating immune deficiencies and autoimmune disorders. As healthcare providers increasingly recognize the efficacy of immunoglobulins, the market is projected to reach 51.0 USD Billion in 2024.
 
This growth is indicative of a broader trend towards personalized medicine, where immunoglobulins play a crucial role in patient care. The increasing prevalence of [chronic diseases](https://www.marketresearchfuture.com/reports/chronic-disease-management-market-981) further fuels this demand, suggesting that the Global Blood Plasma Derivatives Market Industry is poised for sustained expansion.

### Growing Awareness of Rare Diseases

The Global Blood Plasma Derivatives Market Industry is witnessing an increase in awareness and diagnosis of rare diseases, which often require specialized plasma-derived therapies. As healthcare systems improve their capabilities to identify and treat these conditions, the demand for specific plasma derivatives, such as clotting factors and albumin, is expected to rise.
 
This trend is likely to contribute to the market's projected compound annual growth rate of 8.52% from 2025 to 2035. The growing focus on rare diseases underscores the importance of plasma derivatives in modern medicine, positioning the Global Blood Plasma Derivatives Market Industry for significant growth.

### Emerging Markets and Global Expansion

Emerging markets are playing a pivotal role in the growth of the Global Blood Plasma Derivatives Market Industry. Countries in Asia-Pacific and Latin America are experiencing rapid economic development, leading to increased healthcare spending and improved access to plasma-derived therapies.
 
This trend is likely to drive demand for various plasma products, contributing to the overall market growth. As these regions continue to develop their healthcare infrastructure, the Global Blood Plasma Derivatives Market Industry is expected to expand significantly, reflecting the changing dynamics of global healthcare.

### Regulatory Support for Plasma Products

Regulatory frameworks supporting the development and distribution of plasma-derived products are crucial for the Global Blood Plasma Derivatives Market Industry. Governments and health authorities are increasingly recognizing the therapeutic value of these products, leading to streamlined approval processes and enhanced funding for research and development.
 
This supportive environment encourages innovation and investment in the sector, which is essential for meeting the rising global demand for plasma derivatives. As a result, the market is expected to thrive, with projections indicating a substantial increase in value over the coming years.

### Advancements in Plasma Collection Technologies

Technological advancements in plasma collection and processing are significantly impacting the Global Blood Plasma Derivatives Market Industry. Innovations such as automated collection systems and improved separation techniques enhance the efficiency and safety of plasma donation. These advancements not only increase the yield of plasma derivatives but also improve donor experience, thereby attracting more individuals to donate.
 
As a result, the market is likely to benefit from a more robust supply chain, supporting the anticipated growth trajectory towards 125.3 USD Billion by 2035. This evolution in technology indicates a promising future for the Global Blood Plasma Derivatives Market Industry.

## Future Outlook

血漿由来製品市場は、2025年から2035年までの6.47%のCAGRで成長すると予測されており、免疫グロブリンの需要増加と収集技術の進歩が推進要因です。

**New opportunities:**

- 新興市場における血漿採取センターでの拡大。血漿由来製品を利用した新しい治療法の開発。効率向上のためので自動処理テクノロジーへの投資。

2035年までに、市場は堅調な成長を遂げ、バイオ医薬品のリーダーとしての地位を確立することが期待されています。

## Segment Insights

### 用途別：免疫学（最大）対腫瘍学（最も成長している）

血漿由来製品市場は多様な用途スペクトルを示しており、免疫学が市場シェアで先行しています。免疫学は免疫系に関連する疾患に焦点を当てており、さまざまな治療法や療法を取り入れているため、市場の重要な部分を占めています。一方、腫瘍学は、世界中での癌の蔓延と革新的な治療法の開発により、急成長している分野として浮上しています。効果的な癌治療オプションの需要が市場の用途の限界を押し広げています。

免疫学：支配的対腫瘍学：新興

免疫学は血漿由来製品市場において支配的な用途として際立っており、自己免疫疾患の治療や免疫療法の支援に広く使用されているためです。免疫療法に関する認識の向上と進展がその市場地位を強化しています。それに対して、腫瘍学は癌治療に対する関心の高まりにより、新興分野として認識されています。血漿由来製品を活用した腫瘍療法の研究開発が進行中であり、成長のための多くの機会を生み出しています。この分野は、製薬会社が癌治療ソリューションに革新を続け、投資する中で注目を集めており、腫瘍学は進化する市場環境における重要な領域として位置付けられています。

### 製品タイプ別：アルブミン（最大）対免疫グロブリン（最も成長している）

血漿由来製品市場はさまざまな製品タイプに分かれており、現在アルブミンが市場シェアで先行しています。これは、医療治療や療法における広範な用途により、全体の市場の重要な部分を占めています。免疫グロブリンはその後に続き、免疫不全やその他の状態の治療における治療的利点が注目されるにつれて、消費が増加しています。凝固因子や凝固因子濃縮物も特定の医療ニーズに応えるためにこのセグメントに寄与しており、フィブリノーゲンはその独自の治療用途により注目すべき製品として浮上しています。成長トレンドの観点から、免疫グロブリンは自己免疫疾患の蔓延と免疫療法の需要の高まりにより、血漿由来製品の中で最も成長しているセグメントとして認識されています。医療研究と技術の進展もこの製品タイプの拡大を促進しています。一方、アルブミンは市場での確立された存在により安定しており、今後数年間にわたって支配的なプレーヤーとしての役割を確保しています。このセグメント全体の成長は、血漿由来製品に対する認識の高まりと、世界的に拡大する医療インフラによっても強化されています。

アルブミン（支配的）対免疫グロブリン（新興）

アルブミンは、重症治療や外科手術を含む医療治療における多様な用途により、血漿由来製品市場で支配的な製品タイプとして位置付けられています。その配合の多様性と安全性の実績により、医療専門家の間で好まれる選択肢となっています。一方、免疫グロブリンは、この分野で新興製品と見なされており、さまざまな免疫学的状態の管理における効果により推進されています。臨床応用の数が増加する中で、免疫グロブリンは特に免疫サポートを必要とする慢性疾患の増加に伴い、需要が高まっています。研究が新しい治療の可能性を明らかにし続ける中で、両製品は市場環境において重要な関連性を維持する可能性が高いです。

### 最終用途別：病院（最大）対血液バンク（最も成長している）

血漿由来製品市場において、病院は最大のセグメントを占めており、手術や外傷治療を含むさまざまな治療における血漿製品の重要な必要性を反映しています。このセグメントの大きな市場シェアは、病院の入院患者数の増加と、血漿由来製品が効果的に管理するために必要な慢性疾患の蔓延によって推進されています。さらに、血液バンクは、血漿寄付の重要性に対する認識の高まりと収集技術の改善に応じて、最も成長しているセグメントです。

病院（支配的）対血液バンク（新興）

病院は、患者ケアのために血漿製品を広範に使用しているため、血漿由来製品市場で支配的な役割を果たしています。彼らは、重要な治療や療法のためにこれらの製品に大きく依存しており、この市場における主要な消費者としての地位を固めています。それに対して、血液バンクは新興セグメントであり、血漿収集プロセスやドナーアウトリーチプログラムを強化することで勢いを増しています。血液バンクの成長は、血漿由来療法に対する需要の増加と、世界的な健康意識の高まりによって促進されており、血漿由来製品の流通において重要なプレーヤーとなっています。

## Regional Market Share Analysis

### North America : Market Leader in Innovation

North America continues to lead the Blood Plasma Derivatives Market, holding a significant share of 21.8% in 2024. The region's growth is driven by increasing demand for immunoglobulin therapies and advancements in plasma collection technologies. Regulatory support from agencies like the FDA further catalyzes market expansion, ensuring safety and efficacy in plasma-derived products. The rising prevalence of chronic diseases also fuels demand, making North America a pivotal market for blood plasma derivatives.

The competitive landscape in North America is robust, featuring key players such as Grifols, CSL Behring, and Takeda Pharmaceutical Company Limited. These companies are investing heavily in R&D to innovate and expand their product portfolios. The presence of advanced healthcare infrastructure and a well-established reimbursement framework enhances market attractiveness. As the region continues to innovate, it is expected to maintain its leadership position in the global market.

### Europe : Emerging Market with Growth Potential

Europe's Blood Plasma Derivatives Market is poised for growth, with a market size of €12.9 billion. The region benefits from a strong regulatory framework and increasing investments in healthcare infrastructure. Demand for plasma-derived therapies is rising, driven by an aging population and the prevalence of autoimmune diseases. European regulations ensure high safety standards, which further boosts consumer confidence and market growth. The region's collaborative research initiatives also play a crucial role in advancing plasma technology.

Leading countries in Europe include Germany, France, and the UK, where major players like Octapharma and LFB Group are actively expanding their operations. The competitive landscape is characterized by strategic partnerships and mergers aimed at enhancing product offerings. As the market evolves, Europe is expected to become a significant player in the global blood plasma derivatives sector, leveraging its strong research capabilities and regulatory support.

### Asia-Pacific : Rapidly Growing Market Dynamics

The Asia-Pacific region is witnessing rapid growth in the Blood Plasma Derivatives Market, with a market size of $7.5 billion. Factors such as increasing healthcare expenditure, rising awareness about plasma therapies, and a growing patient population are driving this expansion. Governments in the region are also implementing supportive regulations to enhance plasma collection and processing, which is crucial for meeting the rising demand for plasma-derived products. The region's diverse healthcare needs present significant opportunities for market players.

Countries like China and Japan are leading the charge, with companies such as Hualan Biological Engineering Inc. and Takeda Pharmaceutical Company Limited making substantial investments. The competitive landscape is evolving, with local players emerging alongside established global firms. As the region continues to develop its healthcare infrastructure, the demand for blood plasma derivatives is expected to surge, positioning Asia-Pacific as a key market in the global landscape.

### Middle East and Africa : Emerging Market with Challenges

The Blood Plasma Derivatives Market in the Middle East and Africa is still in its nascent stages, with a market size of $1.1 billion. The region faces challenges such as limited healthcare infrastructure and regulatory hurdles, which hinder market growth. However, increasing awareness of plasma therapies and rising healthcare investments are beginning to change the landscape. Governments are starting to recognize the importance of plasma-derived products, which could lead to more supportive regulations in the future.

Countries like South Africa and the UAE are showing potential for growth, with local companies and international players exploring opportunities. The competitive landscape is gradually evolving, with a focus on improving plasma collection and processing capabilities. As the region addresses its challenges, the Blood Plasma Derivatives Market is expected to gain traction, driven by increasing demand for therapeutic products and improved healthcare access.

## Competitive Benchmarking

The Blood Plasma Derivatives Market is characterized by a dynamic competitive landscape, driven by increasing demand for immunoglobulins and clotting factor concentrates. Key players are actively pursuing strategies that emphasize innovation, regional expansion, and strategic partnerships to enhance their market positions. For instance, Grifols (ES) has focused on expanding its product portfolio through research and development, while CSL Behring (AU) has been enhancing its global footprint by investing in new manufacturing facilities.
 
These strategies collectively contribute to a moderately fragmented market structure, where the influence of major players is significant but not overwhelming, allowing for niche players to thrive. In terms of business tactics, companies are increasingly localizing manufacturing to reduce supply chain vulnerabilities and optimize logistics. This approach not only enhances operational efficiency but also aligns with the growing demand for rapid access to plasma-derived therapies. The competitive structure of the market appears to be moderately fragmented, with several key players exerting considerable influence, yet leaving room for smaller entities to carve out their niches through specialized offerings.
 
In November 2025, Takeda Pharmaceutical Company Limited (JP) announced a strategic partnership with a leading biotechnology firm to co-develop a novel immunoglobulin therapy. This collaboration is poised to leverage both companies' strengths in research and development, potentially accelerating the time-to-market for innovative therapies. Such partnerships are indicative of a broader trend where companies seek to pool resources and expertise to navigate the complexities of drug development in the plasma derivatives sector. 
 
In October 2025, Octapharma (CH) unveiled plans to invest €100 million in expanding its production capabilities in Switzerland. This investment is strategically significant as it aims to enhance the company's ability to meet the rising global demand for plasma-derived products. By increasing production capacity, Octapharma positions itself to capture a larger market share while ensuring a reliable supply of critical therapies.
 
In September 2025, Kedrion S.p.A. (IT) launched a new initiative focused on sustainability within its operations, aiming to reduce its carbon footprint by 30% by 2030. This move not only aligns with global sustainability trends but also enhances the company's reputation among environmentally conscious stakeholders. Such initiatives are becoming increasingly vital as consumers and healthcare providers prioritize sustainability in their purchasing decisions.
 
As of December 2025, the Blood Plasma Derivatives Market is witnessing a shift towards digitalization and AI integration, which are redefining competitive dynamics. Companies are increasingly forming strategic alliances to enhance their technological capabilities and streamline operations. The focus appears to be shifting from price-based competition to differentiation through innovation, technology, and supply chain reliability. This evolution suggests that future competitive advantages will likely hinge on the ability to deliver high-quality, innovative products while maintaining operational excellence.

## Recent News & Developments

In August 2026, It secures continuity of supply for a major U.S. immunoglobulin brand and signals ongoing inter-company commercial cooperation among two of the market's largest plasma fractionators, reducing near-term supply risk for patients on GAMMAKED. Kedrion Biopharma announced an extension of its long-standing commercial agreement with Grifols under which Kedrion continues to market GAMMAKED® (Immune Globulin Injection 10%) in the U.S. for primary immunodeficiency, ITP, and CIDP patients. (Source: [kedrion.us](https://www.kedrion.us/kedrion-biopharma-announces-the-extension-of-a-u-s-agreement-with-grifols-to-support-long-term-and-continued-access-to-gammaked/))

In July 2026, It's a significant emerging-market infrastructure play, expanding Takeda's global plasma-sourcing footprint and supporting local self-sufficiency in PDMPs — a growth strategy also being pursued by Grifols in Egypt. Takeda and the Indonesian Ministry of Health, together with two other ministries, announced a collaboration to build a domestic plasma ecosystem, marked by a fractionation license and an initial ~$30 million investment, including a pilot national plasma-donation network. (Source: [takeda.com](https://www.takeda.com/newsroom/newsreleases/2026/takeda-indonesia-plasma-collaboration/))

## Report Scope

| 市場規模 2024 | 433(億米ドル) |
| --- | --- |
| 市場規模 2025 | 466(億米ドル) |
| 市場規模 2035 | 866.7(億米ドル) |
| 年平均成長率 (CAGR) | 6.47% (2025 - 2035) |
| レポートの範囲 | 収益予測、競争環境、成長要因、トレンド |
| 基準年 | 2024 |
| 市場予測期間 | 2025 - 2035 |
| 歴史データ | 2019 - 2024 |
| 市場予測単位 | 億米ドル |
| 主要企業のプロファイル | グリフォルス (ES), CSLベーリング (AU), 武田薬品工業株式会社 (JP), オクタファーマ (CH), ケドリオン S.p.A. (IT), バイオプロダクツラボラトリー (GB), LFBグループ (FR), 華南生物工学株式会社 (CN) |
| カバーされるセグメント | アプリケーション、製品タイプ、最終用途 |
| 主要市場機会 | 治療アプリケーションの進展が血漿誘導物質市場の成長を促進します。 |
| 主要市場ダイナミクス | 免疫グロブリンの需要の高まりが血漿誘導物質市場におけるイノベーションと競争を促進します。 |
| カバーされる国 | 北米、ヨーロッパ、APAC、南米、MEA |

## Frequently Asked Questions

**Q: 2024年の血漿派生物市場の現在の評価額はどのくらいですか？**
A: 血漿派生物市場は2024年に433億米ドルと評価されました。

**Q: 2035年までの血漿派生物市場の予測市場規模はどのくらいですか？**
A: 市場は2035年までに866.7億米ドルに達すると予測されています。

**Q: 2025年から2035年の予測期間中の血漿派生物市場の期待CAGRはどのくらいですか？**
A: 2025年から2035年の予測期間中の市場の期待CAGRは6.47%です。

**Q: 血漿派生物市場の成長を促進しているアプリケーションセグメントはどれですか？**
A: アプリケーションセグメントには、免疫学、血液学、神経学、腫瘍学、感染症が含まれ、評価額は65億から223.5億米ドルの範囲です。

**Q: 血漿派生物市場の主要な製品タイプは何ですか？**
A: 主要な製品タイプには、アルブミン、免疫グロブリン、凝固因子、凝固因子濃縮物、フィブリノーゲンが含まれ、評価額は50億から300億米ドルの範囲です。

**Q: 血漿派生物市場の主要企業はどこですか？**
A: 市場の主要プレーヤーには、グリフォルス、CSLベーリング、武田薬品工業株式会社、オクタファーマ、ケドリオンS.p.A.が含まれます。

**Q: 血漿派生物市場に貢献している最終用途セグメントは何ですか？**
A: 最終用途セグメントには、病院、クリニック、研究所、血液銀行、製薬会社が含まれ、評価額は60億から246.7億米ドルの範囲です。

**Q: 免疫グロブリンの市場は他の製品タイプと比べてどうですか？**
A: 免疫グロブリンは150億から300億米ドルの評価額を持つと予測されており、主要な製品タイプの一つです。

**Q: 血漿派生物市場における腫瘍学セグメントの重要性は何ですか？**
A: 腫瘍学セグメントは90億から180億米ドルに成長すると予測されており、市場拡大における重要な役割を示しています。

**Q: 研究所は血漿派生物市場でどのように位置づけられていますか？**
A: 研究所は70億から140億米ドルの貢献が期待されており、市場における重要性を強調しています。


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/blood-plasma-derivatives-market-1325*